IML is managed by a Board of Directors, consisting of the two founding directors, Eddie Blair & Tito Bacarese-Hamilton. IML also has an advisory group of seven business people, strategists and scientists.
Dr Blair is a molecular biologist/ biochemist with 25 years experience in the pharmaceutical industry, recently as a Director of Applied Diagnostics and Surrogates at GlaxoSmithKline, and is a visiting scholar at Cambridge University.
He has been involved in all aspects of early phase drug development from target identification & routine compound screening through to pre-clinical development & Phase II clinical trials. He has developed programmes that support the strategic integration of surrogate biomarkers & diagnostics into the drug development pipe-line from candidate selection to approval & launch. His broad therapeutic area experience includes viral, respiratory, liver and neurodegenerative disease, frequently in collaboration with esteemed academic groups and he was an initial recruit to the GSK Predictive Medicine Group, where he lead pioneering work on integration of testing with influenza, herpes and hepatitis C virus drug development. He is an expert in the field of virology having published more than 30 papers, edited two books and invented 6 patents in the field.
Tito is current CEO of PredictImmune Ltd, a company developing tests to predict the clinical outcomes of immune-mediated disease.
Tito graduated from King’s College, London and earned his PhD at the Royal Postgraduate Medical Centre in London. He is a Fellow of the American National Association of Clinical Biochemistry and has published more than 50 peer-reviewed articles on a variety of topics related to pathology, oncology and laboratory medicine; he also holds various patents relating to diagnostics.
Tito brings more than 25 years of research and industrial experience in the medical and life sciences areas. He has a broad-based background in medical research and diagnostic product development, biotechnology, drug development programs and general management. He is an acknowledged expert in the field of in vitro diagnostics and has launched numerous products in many clinical fields.
Most recently, Tito was CEO and co-founder of Microtest Matrices Ltd, a protein chip company. Prior to this role, he held senior R & D positions at Ares-Serono and Amersham International.